Cargando…
Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia
Relapse occurs frequently after treatment of acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase 3-internal tandem duplication (ITD) mutation. The availability of immunologic biomarkers to predict patients at high risk could allow clinicians to accelerate alternative treatments s...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701796/ https://www.ncbi.nlm.nih.gov/pubmed/23616009 http://dx.doi.org/10.1007/s00277-013-1744-y |
_version_ | 1782275705725255680 |
---|---|
author | Rickmann, Mareike Macke, Laura Sundarasetty, Bala Sai Stamer, Kathrin Figueiredo, Constanca Blasczyk, Rainer Heuser, Michael Krauter, Juergen Ganser, Arnold Stripecke, Renata |
author_facet | Rickmann, Mareike Macke, Laura Sundarasetty, Bala Sai Stamer, Kathrin Figueiredo, Constanca Blasczyk, Rainer Heuser, Michael Krauter, Juergen Ganser, Arnold Stripecke, Renata |
author_sort | Rickmann, Mareike |
collection | PubMed |
description | Relapse occurs frequently after treatment of acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase 3-internal tandem duplication (ITD) mutation. The availability of immunologic biomarkers to predict patients at high risk could allow clinicians to accelerate alternative treatments such as stem cell transplantation, immunotherapy, or novel drugs. We have previously reported that first diagnostic (FD) ITD(+) AML showed immunophenotypic and functional characteristics of arrested dendritic cell (DC) precursors. In this study, we show that the high frequency of precursor DCs in 16 FD ITD(+) AML samples (Lin(−)/HLA-DR(+)/CD11c(+)/CD123(+)) was associated with a lack of terminal DCs (myeloid DCs: BDCA-1(+) or BDCA-3(+); plasmacytoid DC: BDCA-2(+)). We further evaluated prospectively the peripheral blood complete remission (CR) samples obtained from 11 ITD(+) AML patients after chemotherapy regarding the frequency of DCs and their pattern of cytokine production. Whereas the aberrant frequencies of precursor and terminal plasmacytoid DCs resolved during remission, the myeloid DC compartment did not fully recover. For an available cohort of patients (n = 4) who could be monitored over a period of >15 months after FD, we identified IL-10, TNF-α, IL-6, and IL-1β as cytokines produced by the CR samples at high levels a few months prior to relapse. Cell-free supernatant of an FD ITD(+) AML sample stimulated monocytes obtained from two healthy donors to secrete IL-10, TNF-α, IL-6, and IL-1β. Thus, we hypothesize that ITD(+) AML minimal residual disease can act directly as dysfunctional antigen-presenting cells or indirectly by production of factors that convert monocytes into myeloid-derived suppressor cells secreting cytokines that promote immune evasion. Monitoring these immunologic biomarkers could improve prediction of relapse. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00277-013-1744-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3701796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-37017962013-07-10 Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia Rickmann, Mareike Macke, Laura Sundarasetty, Bala Sai Stamer, Kathrin Figueiredo, Constanca Blasczyk, Rainer Heuser, Michael Krauter, Juergen Ganser, Arnold Stripecke, Renata Ann Hematol Original Article Relapse occurs frequently after treatment of acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase 3-internal tandem duplication (ITD) mutation. The availability of immunologic biomarkers to predict patients at high risk could allow clinicians to accelerate alternative treatments such as stem cell transplantation, immunotherapy, or novel drugs. We have previously reported that first diagnostic (FD) ITD(+) AML showed immunophenotypic and functional characteristics of arrested dendritic cell (DC) precursors. In this study, we show that the high frequency of precursor DCs in 16 FD ITD(+) AML samples (Lin(−)/HLA-DR(+)/CD11c(+)/CD123(+)) was associated with a lack of terminal DCs (myeloid DCs: BDCA-1(+) or BDCA-3(+); plasmacytoid DC: BDCA-2(+)). We further evaluated prospectively the peripheral blood complete remission (CR) samples obtained from 11 ITD(+) AML patients after chemotherapy regarding the frequency of DCs and their pattern of cytokine production. Whereas the aberrant frequencies of precursor and terminal plasmacytoid DCs resolved during remission, the myeloid DC compartment did not fully recover. For an available cohort of patients (n = 4) who could be monitored over a period of >15 months after FD, we identified IL-10, TNF-α, IL-6, and IL-1β as cytokines produced by the CR samples at high levels a few months prior to relapse. Cell-free supernatant of an FD ITD(+) AML sample stimulated monocytes obtained from two healthy donors to secrete IL-10, TNF-α, IL-6, and IL-1β. Thus, we hypothesize that ITD(+) AML minimal residual disease can act directly as dysfunctional antigen-presenting cells or indirectly by production of factors that convert monocytes into myeloid-derived suppressor cells secreting cytokines that promote immune evasion. Monitoring these immunologic biomarkers could improve prediction of relapse. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00277-013-1744-y) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2013-04-25 2013 /pmc/articles/PMC3701796/ /pubmed/23616009 http://dx.doi.org/10.1007/s00277-013-1744-y Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Article Rickmann, Mareike Macke, Laura Sundarasetty, Bala Sai Stamer, Kathrin Figueiredo, Constanca Blasczyk, Rainer Heuser, Michael Krauter, Juergen Ganser, Arnold Stripecke, Renata Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia |
title | Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia |
title_full | Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia |
title_fullStr | Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia |
title_full_unstemmed | Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia |
title_short | Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia |
title_sort | monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with flt3-itd acute myeloid leukemia |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3701796/ https://www.ncbi.nlm.nih.gov/pubmed/23616009 http://dx.doi.org/10.1007/s00277-013-1744-y |
work_keys_str_mv | AT rickmannmareike monitoringdendriticcellandcytokinebiomarkersduringremissionpriortorelapseinpatientswithflt3itdacutemyeloidleukemia AT mackelaura monitoringdendriticcellandcytokinebiomarkersduringremissionpriortorelapseinpatientswithflt3itdacutemyeloidleukemia AT sundarasettybalasai monitoringdendriticcellandcytokinebiomarkersduringremissionpriortorelapseinpatientswithflt3itdacutemyeloidleukemia AT stamerkathrin monitoringdendriticcellandcytokinebiomarkersduringremissionpriortorelapseinpatientswithflt3itdacutemyeloidleukemia AT figueiredoconstanca monitoringdendriticcellandcytokinebiomarkersduringremissionpriortorelapseinpatientswithflt3itdacutemyeloidleukemia AT blasczykrainer monitoringdendriticcellandcytokinebiomarkersduringremissionpriortorelapseinpatientswithflt3itdacutemyeloidleukemia AT heusermichael monitoringdendriticcellandcytokinebiomarkersduringremissionpriortorelapseinpatientswithflt3itdacutemyeloidleukemia AT krauterjuergen monitoringdendriticcellandcytokinebiomarkersduringremissionpriortorelapseinpatientswithflt3itdacutemyeloidleukemia AT ganserarnold monitoringdendriticcellandcytokinebiomarkersduringremissionpriortorelapseinpatientswithflt3itdacutemyeloidleukemia AT stripeckerenata monitoringdendriticcellandcytokinebiomarkersduringremissionpriortorelapseinpatientswithflt3itdacutemyeloidleukemia |